aibio
Company Updates ·
Sonoma Pharmaceuticals adopts new Section 382 rights agreement
The board replaced an expiring rights agreement with one meant to protect net operating loss carryforwards, with rights tied to holders of record on October 13, 2026.
SNOA Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals (SNOA) news SNOA offering news
Latest Sonoma Pharmaceuticals news
- Company Updates
Sonoma Pharmaceuticals lifts at-the-market offering ceiling to $3,641,703
A prospectus supplement filed June 18, 2026 raises the aggregate offering price under the company's sales agreement with Ladenburg Thalmann to $3,641,703.
What Sonoma Pharmaceuticals does
Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products for wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company sells its products directly or through partners in over 55 countries. Its dermatology products target pain and itch from skin irritations, scar management and symptoms of eczema or atopic dermatitis, including Epicyn Facial Cleanser, Levicyn, Celacyn Scar Management Gel and Regenacyn Advanced Scar Gel. Recent business updates in the text include a March 2026 U.S. retail launch of an HOCl burn relief hydrogel in CVS and Walmart stores, the launch of Aquanil AD for Persōn & Covey, Inc., and an October 2025 launch of an HOCl wound cleanser for Medline Industries, LP. The company also reports regulatory approval for its wound care products in Ukraine as a Class IIb medical device, received in April 2025. Its fiscal year ends March 31.
| Product or program | What it is | Stage |
|---|---|---|
| Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel | HOCl hydrogel for red bumps, rashes, shallow skin fissures and eczema symptoms | over-the-counter in the United States |
| HOCl burn relief hydrogel | Burn relief hydrogel sold in CVS and Walmart stores | U.S. retail launch, March 2026 |
| Aquanil AD | HOCl dermatology product line for sensitive skin, developed for Persōn & Covey | launch announced March 2026 |
| HOCl wound cleanser | Wound cleanser developed for Medline for hospital and home healthcare channels | launch announced October 2025 |
Sonoma Pharmaceuticals annual financials
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Revenue | $19.5 million | $14.3 million |
| Research and development | $2.3 million | $1.8 million |
| Net income (loss) | -$3.2 million | -$3.5 million |
| Cash from operations | -$3.9 million | -$88,000 |
| Cash and equivalents | $2.4 million | $5.4 million |
Questions about Sonoma Pharmaceuticals
Has Sonoma Pharmaceuticals raised money recently?
Our latest story on this, dated Jun 18, 2026: "Sonoma Pharmaceuticals lifts at-the-market offering ceiling to $3,641,703". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals, Inc. trades under the ticker SNOA on NASDAQ.
Where is Sonoma Pharmaceuticals listed?
Sonoma Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of Sonoma Pharmaceuticals?
The SEC Central Index Key (CIK) for Sonoma Pharmaceuticals, Inc. is 1367083. Its filings are on SEC EDGAR.
How many shares does Sonoma Pharmaceuticals have outstanding?
4,788,425 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Sonoma Pharmaceuticals listed under?
Our directory records Sonoma Pharmaceuticals, Inc. under United States.
What does Sonoma Pharmaceuticals do?
Our directory classifies Sonoma Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Sonoma Pharmaceuticals?
The ISIN recorded for Sonoma Pharmaceuticals, Inc. is US83558L3033.
Does aibio.space cover Sonoma Pharmaceuticals?
aibio.space lists Sonoma Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Sonoma Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
What does Sonoma Pharmaceuticals develop?
Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products for wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company sells its products directly or through partners in over 55 countries.
What is Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel from Sonoma Pharmaceuticals?
Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel: HOCl hydrogel for red bumps, rashes, shallow skin fissures and eczema symptoms Stage: over-the-counter in the United States.
What is HOCl burn relief hydrogel from Sonoma Pharmaceuticals?
HOCl burn relief hydrogel: Burn relief hydrogel sold in CVS and Walmart stores Stage: U.S. retail launch, March 2026.
What was Sonoma Pharmaceuticals's revenue last year?
$19.5 million for the fiscal year ended Mar 31, 2026, as reported to the SEC.
Is Sonoma Pharmaceuticals profitable?
Sonoma Pharmaceuticals, Inc. reported a net loss of $3.2 million for the fiscal year ended Mar 31, 2026, and used $3.9 million of cash in operations, per its annual report to the SEC.
Investor discussion: Sonoma Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Sonoma Pharmaceuticals, Inc.
- CIK
- 1367083
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus (3841)
- US tickers
- SNOA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- March 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 5445 CONESTOGA COURT, SUITE 150, BOULDER, CO, 80301
- Phone
- 800-759-9305
- Shares outstanding
- 4,788,425 as of 2026-08-06 (10-Q filed 2026-08-06)
- Former names
- Oculus Innovative Sciences, Inc.
Recent filings
Listing details
- Company
- Sonoma Pharmaceuticals, Inc.
- Ticker
- SNOA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US83558L3033
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction